دورية أكاديمية
Identification of Lignan Compounds as New 6-Phosphogluconate Dehydrogenase Inhibitors for Lung Cancer.
| العنوان: | Identification of Lignan Compounds as New 6-Phosphogluconate Dehydrogenase Inhibitors for Lung Cancer. |
|---|---|
| المؤلفون: | Khan GB; Department of Bioinformatics and Biotechnology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan., Qasim M; Department of Bioinformatics and Biotechnology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan., Rasul A; Department of Zoology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan., Ashfaq UA; Department of Bioinformatics and Biotechnology, Faculty of Life Sciences, Government College University, Faisalabad 38000, Pakistan., Alnuqaydan AM; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia. |
| المصدر: | Metabolites [Metabolites] 2022 Dec 24; Vol. 13 (1). Date of Electronic Publication: 2022 Dec 24. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101578790 Publication Model: Electronic Cited Medium: Print ISSN: 2218-1989 (Print) Linking ISSN: 22181989 NLM ISO Abbreviation: Metabolites Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel : MDPI |
| مستخلص: | Targeting pentose phosphate pathway (PPP) enzymes has emerged as a promising strategy to combat cancer. 6-Phosphogluconate dehydrogenase (6-PGD), the third critical enzyme of the PPP, catalyzes oxidative decarboxylation of 6-phosphogluconate (6-PG) to produce ribulose-5-phosphate (Ru-5-P) and CO2. Overexpression of 6-PGD has been reported in multiple cancers and is recognized as a potential anticancer drug target. The current study is focused on the utilization of indispensable virtual screening tools for structure-based drug discovery. During the study, 17,000 natural compounds were screened against the 3-phosphoglycerate (3-PG) binding site of 6-PGD through a molecular operating environment (MOE), which revealed 115 inhibitors with higher selectivity and binding affinity. Out of the 115 best-fit compounds within the 6-PGD binding cavity, 15 compounds were selected and optimized through stringent in silico ADMET assessment models that justified the desirable pharmacokinetic, pharmacodynamic and physicochemical profiles of 5 ligands. Further protein−ligand stability assessment through molecular dynamics (MD) simulation illustrated three potential hits, secoisolariciresinol, syringaresinol and cleomiscosin A, with stable confirmation. Moreover, 6-PGD inhibitor validation was performed by an in vitro enzymatic assay using human erythrocytes purified 6-PGD protein and A549 cell lysate protein. The results of the in vitro assays supported the in silico findings. In order to gain insight into the anticancer activity of the aforementioned compounds, they were subjected to CLC-Pred, an in silico cytotoxicity browsing tool, which proved their anticancer activity against several cancer cell lines at Pa > 0.5. Additionally, a confirmation for in silico cytotoxicity was made by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for commercially available hits syringaresinol and cleomiscosin A against lung cancer (A549) cells. The results demonstrated that syringaresinol has an IC50 value of 36.9 μg/mL, while cleomiscosin A has an IC50 value of 133 μg/mL. After MTT, flow cytometry analysis confirmed that compounds induced apoptosis in A549 cells in a dose-dependent manner. This study suggested that the respective lignan compounds can serve as lead candidates for lung cancer therapy via 6-PGD inhibition. Furthermore, in vivo experiments need to be conducted to confirm their efficacy. |
| References: | Oncol Rep. 2012 May;27(5):1481-7. (PMID: 22367117) J Med Chem. 2015 May 14;58(9):4066-72. (PMID: 25860834) Pharm Biol. 2016 Sep;54(9):1522-7. (PMID: 26809027) Clin Transl Oncol. 2019 Apr;21(4):404-411. (PMID: 30182212) Adv Carbohydr Chem Biochem. 2014;71:9-136. (PMID: 25480504) Sci Transl Med. 2014 Mar 5;6(226):226ra32. (PMID: 24598590) Planta Med. 1998 Oct;64(7):628-31. (PMID: 9810268) Nat Rev Cancer. 2011 Feb;11(2):85-95. (PMID: 21258394) Biomed Pharmacother. 2019 Mar;111:1353-1358. (PMID: 30841449) Part Fibre Toxicol. 2010 Oct 07;7:29. (PMID: 20929559) Cancer Cell. 2008 Jun;13(6):472-82. (PMID: 18538731) Methods Enzymol. 2015;553:65-89. (PMID: 25726461) Free Radic Biol Med. 2012 Aug 1;53(3):421-36. (PMID: 22580150) Int J Angiol. 2000 Oct;9(4):220-225. (PMID: 11062311) Oncogene. 2017 Jan 12;36(2):254-262. (PMID: 27270429) Fitoterapia. 2021 Jan;148:104799. (PMID: 33301798) Arch Pharm Res. 2007 Mar;30(3):275-81. (PMID: 17424931) Int J Mol Sci. 2020 Jan 31;21(3):. (PMID: 32023830) Trends Biochem Sci. 2014 Aug;39(8):347-54. (PMID: 25037503) Biomed Res Int. 2021 May 26;2021:5514669. (PMID: 34136566) Biol Pharm Bull. 2007 Jun;30(6):1164-6. (PMID: 17541175) Adv Drug Deliv Rev. 2016 Jun 1;101:89-98. (PMID: 27182629) PLoS One. 2018 Jan 25;13(1):e0191838. (PMID: 29370280) Arch Pharm Res. 2018 Feb;41(2):192-195. (PMID: 29177586) J Mol Graph. 1996 Feb;14(1):33-8, 27-8. (PMID: 8744570) Clin Transl Oncol. 2018 Sep;20(9):1145-1152. (PMID: 29340974) Nat Prod Res. 2005 Jun;19(4):319-23. (PMID: 15938136) J Chem Inf Model. 2012 Jul 23;52(7):1757-68. (PMID: 22587354) Nat Prod Res. 2017 Jun;31(11):1228-1236. (PMID: 27681445) Sci Rep. 2019 Feb 5;9(1):1433. (PMID: 30723263) Oncol Lett. 2019 May;17(5):4213-4221. (PMID: 30944616) Aging (Albany NY). 2016 Apr;8(4):603-19. (PMID: 27019364) Cancer Cell. 2012 Nov 13;22(5):585-600. (PMID: 23153533) Br J Cancer. 2015 Mar 17;112(6):957-62. (PMID: 25742467) Curr Opin Chem Biol. 2004 Aug;8(4):365-70. (PMID: 15288245) Bioinformation. 2013 Dec 06;9(19):993-5. (PMID: 24391364) J Breast Cancer. 2019 Aug 02;22(3):362-374. (PMID: 31598337) Science. 2013 Oct 11;342(6155):1242454. (PMID: 24115444) Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954. (PMID: 27899562) Front Pharmacol. 2020 Feb 28;11:175. (PMID: 32184731) J Biomol Struct Dyn. 2022 Oct;40(17):7829-7851. (PMID: 33764266) J Transl Med. 2018 Oct 27;16(1):298. (PMID: 30368237) Molecules. 2018 Sep 08;23(9):. (PMID: 30205569) Yale J Biol Med. 2006 Dec;79(3-4):85-94. (PMID: 17940618) Biology (Basel). 2021 Jan 23;10(2):. (PMID: 33498665) Biofactors. 2020 Jul;46(4):550-562. (PMID: 32039535) Nat Cell Biol. 2015 Nov;17(11):1484-96. (PMID: 26479318) Neuropharmacology. 2018 Mar 15;131:68-82. (PMID: 29225041) J Biochem Mol Toxicol. 2018 Sep;32(9):e22193. (PMID: 29992784) Int Immunopharmacol. 2008 Jul;8(7):967-73. (PMID: 18486907) J Clin Med. 2019 Feb 11;8(2):. (PMID: 30754680) Z Naturforsch C J Biosci. 2006 Jan-Feb;61(1-2):35-43. (PMID: 16610214) J Biochem Mol Toxicol. 2014 Nov;28(11):510-4. (PMID: 25130191) Int J Radiat Biol. 2019 Jul;95(7):912-919. (PMID: 30822194) |
| معلومات مُعتمدة: | Deanship of Scientific Research, Qassim University Deanship of Scientific Research, Qassim University |
| فهرسة مساهمة: | Keywords: 6-PGD; MD simulation; docking; enzymatic assay; in silico; natural inhibitors |
| تواريخ الأحداث: | Date Created: 20230121 Latest Revision: 20230308 |
| رمز التحديث: | 20230308 |
| مُعرف محوري في PubMed: | PMC9864769 |
| DOI: | 10.3390/metabo13010034 |
| PMID: | 36676959 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!